Bank of America Issues Pessimistic Forecast for Kura Oncology (NASDAQ:KURA) Stock Price

Kura Oncology (NASDAQ:KURA) had its price target decreased by Bank of America from $36.00 to $29.00 in a research report report published on Friday,Benzinga reports. Bank of America currently has a buy rating on the stock.

KURA has been the topic of a number of other reports. HC Wainwright raised their target price on Kura Oncology from $32.00 to $37.00 and gave the company a “buy” rating in a research note on Thursday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Kura Oncology in a research note on Thursday. JMP Securities reiterated a “market outperform” rating and issued a $32.00 target price on shares of Kura Oncology in a research note on Tuesday, November 19th. Stifel Nicolaus cut Kura Oncology from a “buy” rating to a “hold” rating and cut their target price for the company from $26.00 to $19.00 in a research note on Monday, October 14th. Finally, UBS Group began coverage on Kura Oncology in a report on Thursday, October 24th. They set a “buy” rating and a $27.00 price target on the stock. One analyst has rated the stock with a sell rating, one has issued a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $29.38.

Kura Oncology Stock Performance

KURA stock opened at $10.80 on Friday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. The stock has a market capitalization of $839.81 million, a price-to-earnings ratio of -4.58 and a beta of 0.86. Kura Oncology has a 1 year low of $9.06 and a 1 year high of $24.17. The stock’s fifty day moving average is $17.88 and its two-hundred day moving average is $19.67.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Assenagon Asset Management S.A. grew its holdings in Kura Oncology by 50.1% during the second quarter. Assenagon Asset Management S.A. now owns 1,731,577 shares of the company’s stock worth $35,653,000 after acquiring an additional 577,732 shares during the period. Vanguard Group Inc. grew its holdings in Kura Oncology by 0.7% during the first quarter. Vanguard Group Inc. now owns 4,065,903 shares of the company’s stock worth $86,726,000 after acquiring an additional 28,212 shares during the period. Sofinnova Investments Inc. grew its holdings in Kura Oncology by 64.4% during the second quarter. Sofinnova Investments Inc. now owns 825,243 shares of the company’s stock worth $16,992,000 after acquiring an additional 323,303 shares during the period. Armistice Capital LLC grew its holdings in Kura Oncology by 14.7% during the second quarter. Armistice Capital LLC now owns 2,350,000 shares of the company’s stock worth $48,386,000 after acquiring an additional 302,000 shares during the period. Finally, SG Americas Securities LLC acquired a new position in Kura Oncology during the first quarter worth about $110,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.